MaxCyte (MXCT) Stock Price, News & Analysis

Company Overview

MaxCyte, Inc. is a life sciences company specializing in cell-engineering technologies that enable the development of advanced therapeutics and research applications. At the core of its offering is a proprietary Flow Electroporation platform, which allows for efficient, scalable and gentle delivery of macromolecules—such as nucleic acids, proteins and CRISPR/Cas9 components—into a wide range of cell types. The company’s instruments and reagent consumables are used by biotechnology and pharmaceutical companies for drug discovery, genome editing, cell therapy manufacturing and research workflows.

Its commercial product lines include the STX™ Scalable Transfection System for research and development applications, as well as the ATx™ and VLx™ platforms designed to meet the rigorous requirements of clinical and GMP-grade cell therapy production. In addition to instrument sales, MaxCyte offers transfection reagents and accessories that have been validated across multiple cell types. The company also partners with leading biopharmaceutical organizations to provide contract development and manufacturing services for cell therapy candidates advancing toward clinical trials.

Founded in 1998 and headquartered in Gaithersburg, Maryland, MaxCyte has established a global footprint with additional operations and support centers in Cambridge, United Kingdom, and offices that serve clients throughout North America, Europe and Asia. The company completed its initial public offering on the Nasdaq exchange under the ticker MXCT in 2016, marking a significant milestone in its transition from a technology provider to a commercial-stage life sciences enterprise.

Led by President and Chief Executive Officer Mark J. Cully, MaxCyte’s executive leadership team also includes Chief Financial Officer Trevor Clinger. Under their guidance, the company has formed strategic collaborations with major pharmaceutical and biotechnology firms and continues to expand its customer base, which encompasses both emerging biotech innovators and established global drug developers.

Key Stats

• Today's Range: $2.06 to $2.19
• 50-Day Range: $2.04 to $2.39
• 52-Week Range: $2.00 to $5.20
• Volume: 191,079 shs
• Average Volume: 612,240 shs
• Market Capitalization: $219.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Buy

MaxCyte Stock Analysis - MarketRank™

MaxCyte scored higher than 56% of companies evaluated by MarketBeat, and ranked 458th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MaxCyte has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MaxCyte are expected to grow in the coming year, from ($0.42) to ($0.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MaxCyte is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MaxCyte is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MaxCyte has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.52% of the float of MaxCyte has been sold short.

Short Interest Ratio / Days to Cover

MaxCyte has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MaxCyte has recently decreased by 3.37%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MaxCyte does not currently pay a dividend.

Dividend Growth

MaxCyte does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.52% of the float of MaxCyte has been sold short.

Short Interest Ratio / Days to Cover

MaxCyte has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MaxCyte has recently decreased by 3.37%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.96

News Sentiment

MaxCyte has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for MaxCyte this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MaxCyte insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.30% of the stock of MaxCyte is held by insiders.

Percentage Held by Institutions

68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MXCT Stock Analysis - Frequently Asked Questions

How have MXCT shares performed this year?

MaxCyte's stock was trading at $4.16 at the beginning of 2025. Since then, MXCT stock has decreased by 49.2% and is now trading at $2.1150.

How were MaxCyte's earnings last quarter?

MaxCyte, Inc. (NASDAQ:MXCT) announced its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). The company earned $10.39 million during the quarter, compared to analyst estimates of $9.05 million. MaxCyte had a negative trailing twelve-month return on equity of 19.90% and a negative net margin of 110.92%.
Read the conference call transcript.

When did MaxCyte IPO?

MaxCyte (MXCT) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.

Who are MaxCyte's major shareholders?

MaxCyte's top institutional investors include Farther Finance Advisors LLC (0.01%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, Stanley C Erck, John Joseph Johnston, Douglas J Swirsky, Richard Douglas, Maher Masoud, David I Sandoval, Ali Soleymannezhad and Thomas M Ross.
View institutional ownership trends.

How do I buy shares of MaxCyte?

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:MXCT
• CIK: 1287098
• Web: maxcyte.com
• Phone: 301-944-1700
• Fax: 301-944-1703
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for MaxCyte: $7.50
• High Price Target: $9.00
• Low Price Target: $6.00
• Potential Upside/Downside: +254.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$41.06 million
• Net Margins: -110.92%
• Pretax Margin: -110.92%
• Return on Equity: -19.90%
• Return on Assets: -17.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.23
• Quick Ratio: 11.58

Sales & Book Value

• Annual Sales: $38.63 million
• Price / Sales: 5.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.95 per share
• Price / Book: 1.08

Miscellaneous

• Outstanding Shares: 106,420,000
• Free Float: 102,904,000
• Market Cap: $225.08 million
• Optionable: Optionable
• Beta: 1.23